Business Context and Reporting Period
Company: BioXcel Therapeutics, Inc. (BTAI)
Filing Type: Form 8-K (Current Report)
Date of Report: August 27, 2026
Event: Voluntary Chapter 11 Bankruptcy Filing and Asset Sale Agreement
On August 27, 2026, BioXcel Therapeutics, Inc. and its subsidiaries filed voluntary petitions for relief under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. The company intends to operate as a "debtor-in-possession" while seeking to maximize stakeholder value, primarily through the sale of assets.
Key Financial Metrics and Liquidity
This filing does not provide historical revenue, profit, or cash flow statements. Key financial figures relate to the restructuring and asset sale:
- Debtors-in-Possession (DIP) Financing: Up to $19 million in new money term loans (available in two draws of $9.5 million each) and up to $58.25 million in roll-up loans converting prepetition obligations.
- Asset Sale Consideration (Stalking Horse Bid):
- Upfront cash: $57.5 million.
- Contingent Development Milestone Payments: Up to $67.5 million (tied to sNDA approval for IGALMI at-home use).
- Contingent Commercial Milestone Payments: Up to $20 million (tied to net sales thresholds).
- Liquidity Source: Post-petition operations are expected to be funded by the DIP Financing provided by affiliates of Oaktree Capital Management, L.P. and the Qatar Investment Authority.
Material Changes and Transactions
The most significant material change is the entry into bankruptcy proceedings and the execution of a definitive asset purchase agreement:
- Bankruptcy Filing: The company and subsidiaries (OnkosXcel Therapeutics, LLC and OnkosXcel Employee Holdings, LLC) are now under Chapter 11 protection.
- Stalking Horse Asset Purchase Agreement: Entered into on August 27, 2026, with Teva Pharmaceuticals International GmbH (Teva). Teva agreed to acquire substantially all assets and assume specified liabilities.
- Management Changes: Samir Saleem was appointed Chief Restructuring Officer (CRO) to oversee the restructuring, lender relations, and the sale process. He reports to a Strategic Process Committee of the Board.
Outlook, Risks, and Contingencies
Outlook and Strategy: The company's objective is to sell assets to the highest bidder. The Teva agreement serves as the "floor" bid, subject to an auction process and Court approval. The transaction is expected to close by October 30, 2026, barring termination events.
Key Risks and Contingencies:
- Transaction Approval: The sale is contingent upon Court approval of the bidding procedures and the transaction itself.
- Competing Bids: The transaction remains subject to higher or better bids during the auction process.
- Operational Risks: Potential employee attrition, disruption of supplier/vendor relationships, and increased legal/administrative costs.
- Milestone Uncertainty: Significant portions of the sale price ($87.5 million total potential) are contingent on regulatory approvals (sNDA) and future commercial sales, which may never be achieved.
- Financing Restrictions: The company must comply with restrictions imposed by the DIP Facility terms.
Investor Verification Checklist
- Verify the status of the "First Day Motions" and the interim/final DIP Financing orders in the Delaware Bankruptcy Court.
- Monitor the auction process for competing bids that may exceed the Teva stalking horse offer.
- Review the specific terms of the contingent milestone payments in the Stalking Horse APA to understand the likelihood of realizing the full $145 million potential consideration.
- Check for any objections filed by creditors or other parties regarding the sale motion or bidding procedures.
- Confirm the timeline for the Court hearing on the approval of the bidding procedures and the proposed sale.